Department of Biochemistry and Biotechnology, Khwaja Yunus Ali University, Chouhali, Sirajganj 6751, Bangladesh.
Department of Public Health, Daffodil International University, Birulia, Dhaka 1216, Bangladesh.
Brief Bioinform. 2024 Jul 25;25(5). doi: 10.1093/bib/bbae401.
Pseudomonas aeruginosa is a complex nosocomial infectious agent responsible for numerous illnesses, with its growing resistance variations complicating treatment development. Studies have emphasized the importance of virulence factors OprE and OprF in pathogenesis, highlighting their potential as vaccine candidates. In this study, B-cell, MHC-I, and MHC-II epitopes were identified, and molecular linkers were active to join these epitopes with an appropriate adjuvant to construct a vaccine. Computational tools were employed to forecast the tertiary framework, characteristics, and also to confirm the vaccine's composition. The potency was weighed through population coverage analysis and immune simulation. This project aims to create a multi-epitope vaccine to reduce P. aeruginosa-related illness and mortality using immunoinformatics resources. The ultimate complex has been determined to be stable, soluble, antigenic, and non-allergenic upon inspection of its physicochemical and immunological properties. Additionally, the protein exhibited acidic and hydrophilic characteristics. The Ramachandran plot, ProSA-web, ERRAT, and Verify3D were employed to ensure the final model's authenticity once the protein's three-dimensional structure had been established and refined. The vaccine model showed a significant binding score and stability when interacting with MHC receptors. Population coverage analysis indicated a global coverage rate of 83.40%, with the USA having the highest coverage rate, exceeding 90%. Moreover, the vaccine sequence underwent codon optimization before being cloned into the Escherichia coli plasmid vector pET-28a (+) at the EcoRI and EcoRV restriction sites. Our research has developed a vaccine against P. aeruginosa that has strong binding affinity and worldwide coverage, offering an acceptable way to mitigate nosocomial infections.
铜绿假单胞菌是一种复杂的医院感染病原体，可导致多种疾病，其不断增加的耐药变异使治疗开发变得复杂。研究强调了毒力因子 OprE 和 OprF 在发病机制中的重要性，突出了它们作为疫苗候选物的潜力。在这项研究中，鉴定了 B 细胞、MHC-I 和 MHC-II 表位，并使分子接头活跃，将这些表位与适当的佐剂连接起来，构建疫苗。计算工具用于预测三级结构、特性，并确认疫苗的组成。通过群体覆盖分析和免疫模拟来衡量效力。本项目旨在使用免疫信息学资源开发一种多表位疫苗，以降低铜绿假单胞菌相关疾病和死亡率。经过物理化学和免疫学特性检查，最终确定该复合物是稳定的、可溶的、抗原的和无变应原性的。此外，该蛋白表现出酸性和亲水性特征。Ramachandran 图、ProSA-web、ERRAT 和 Verify3D 被用来确保在建立和完善蛋白质的三维结构后，最终模型的真实性。疫苗模型在与 MHC 受体相互作用时表现出显著的结合评分和稳定性。群体覆盖分析表明，全球覆盖率为 83.40%，其中美国的覆盖率最高，超过 90%。此外，在将疫苗序列克隆到大肠杆菌质粒载体 pET-28a (+)的 EcoRI 和 EcoRV 限制位点之前，对其进行了密码子优化。我们的研究开发了一种针对铜绿假单胞菌的疫苗，具有很强的结合亲和力和全球覆盖范围，为减轻医院感染提供了一种可行的方法。
